199 related articles for article (PubMed ID: 29037813)
21. Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease.
Szanto I; Rubbia-Brandt L; Kiss P; Steger K; Banfi B; Kovari E; Herrmann F; Hadengue A; Krause KH
J Pathol; 2005 Oct; 207(2):164-76. PubMed ID: 16086438
[TBL] [Abstract][Full Text] [Related]
22. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model.
Hamzah J; Altin JG; Herringson T; Parish CR; Hämmerling GJ; O'Donoghue H; Ganss R
J Immunol; 2009 Jul; 183(2):1091-8. PubMed ID: 19561111
[TBL] [Abstract][Full Text] [Related]
23. Liposomes for targeting of antigens and drugs: immunoadjuvant activity and liposome-mediated depletion of macrophages.
van Rooijen N
J Drug Target; 2008 Aug; 16(7):529-34. PubMed ID: 18686122
[TBL] [Abstract][Full Text] [Related]
24. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes.
Xiang Y; Liang L; Wang X; Wang J; Zhang X; Zhang Q
J Control Release; 2011 Jun; 152(3):402-10. PubMed ID: 21435361
[TBL] [Abstract][Full Text] [Related]
25. Selective liposome targeting of folate receptor positive immune cells in inflammatory diseases.
Poh S; Chelvam V; Ayala-López W; Putt KS; Low PS
Nanomedicine; 2018 Apr; 14(3):1033-1043. PubMed ID: 29410110
[TBL] [Abstract][Full Text] [Related]
26. New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy.
Teruel AH; Gonzalez-Alvarez I; Bermejo M; Merino V; Marcos MD; Sancenon F; Gonzalez-Alvarez M; Martinez-Mañez R
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899548
[TBL] [Abstract][Full Text] [Related]
27. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
[TBL] [Abstract][Full Text] [Related]
28. The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells.
Aharoni R; Sonego H; Brenner O; Eilam R; Arnon R
Immunol Lett; 2007 Oct; 112(2):110-9. PubMed ID: 17719654
[TBL] [Abstract][Full Text] [Related]
29. An increased adjuvanticity of liposomes by the inclusion of phosphatidylserine in immunization with surface-coupled liposomal antigen.
Mori M; Nishida M; Maekawa N; Yamamura H; Tanaka Y; Kasai M; Taneichi M; Uchida T
Int Arch Allergy Immunol; 2005 Jan; 136(1):83-9. PubMed ID: 15591816
[TBL] [Abstract][Full Text] [Related]
30. Accumulation of liposome with Sialyl Lewis X to inflammation and tumor region: application to in vivo bio-imaging.
Hirai M; Minematsu H; Kondo N; Oie K; Igarashi K; Yamazaki N
Biochem Biophys Res Commun; 2007 Feb; 353(3):553-8. PubMed ID: 17189617
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of pulmonary surfactant protein A like molecules in inflammatory bowel disease tissues.
Luo JM; Liu ZQ; Eugene CY
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Nov; 33(11):979-86. PubMed ID: 19060364
[TBL] [Abstract][Full Text] [Related]
32. Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size.
Allen TM; Austin GA; Chonn A; Lin L; Lee KC
Biochim Biophys Acta; 1991 Jan; 1061(1):56-64. PubMed ID: 1995057
[TBL] [Abstract][Full Text] [Related]
33. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
[TBL] [Abstract][Full Text] [Related]
34. A self-assembled, ROS-responsive Janus-prodrug for targeted therapy of inflammatory bowel disease.
Li S; Xie A; Li H; Zou X; Zhang Q
J Control Release; 2019 Dec; 316():66-78. PubMed ID: 31682913
[TBL] [Abstract][Full Text] [Related]
35. Imaging-based analysis of liposome internalization to macrophage cells: Effects of liposome size and surface modification with PEG moiety.
Lee JS; Hwang SY; Lee EK
Colloids Surf B Biointerfaces; 2015 Dec; 136():786-90. PubMed ID: 26529386
[TBL] [Abstract][Full Text] [Related]
36. An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease.
Zhang S; Ermann J; Succi MD; Zhou A; Hamilton MJ; Cao B; Korzenik JR; Glickman JN; Vemula PK; Glimcher LH; Traverso G; Langer R; Karp JM
Sci Transl Med; 2015 Aug; 7(300):300ra128. PubMed ID: 26268315
[TBL] [Abstract][Full Text] [Related]
37. Effect of space length of mannose ligand on uptake of mannosylated liposome in RAW 264.7 cells: In vitro and in vivo studies.
Jeong HS; Na KS; Hwang H; Oh PS; Kim DH; Lim ST; Sohn MH; Jeong HJ
J Biomed Mater Res A; 2014 Dec; 102(12):4545-53. PubMed ID: 24677479
[TBL] [Abstract][Full Text] [Related]
38. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
[TBL] [Abstract][Full Text] [Related]
39. Fluorescent liposomes as contrast agents for in vivo optical imaging of edemas in mice.
Deissler V; Rüger R; Frank W; Fahr A; Kaiser WA; Hilger I
Small; 2008 Aug; 4(8):1240-6. PubMed ID: 18666163
[TBL] [Abstract][Full Text] [Related]
40. Liposomal formulations of inflammatory bowel disease drugs: local versus systemic drug delivery in a rat model.
Kesisoglou F; Zhou SY; Niemiec S; Lee JW; Zimmermann EM; Fleisher D
Pharm Res; 2005 Aug; 22(8):1320-30. PubMed ID: 16078142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
